NDAORALTABLET
Approved
Oct 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Androgen Receptor Antagonists
Pharmacologic Class:
Androgen Receptor Inhibitor
Clinical Trials (5)
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Started Apr 2024
53 enrolled
Triple Negative Breast Neoplasms
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Started Apr 2019
30 enrolled
Breast Neoplasm FemaleBreast CancerBreast Carcinoma+1 more
Ribociclib and Bicalutamide in AR+ TNBC
Started May 2018
37 enrolled
Triple Negative Breast Cancer
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
Started Nov 2015
46 enrolled
Metastatic Breast Cancer (MBC)
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
Started Oct 2014
6 enrolled
Non Castrate Metastatic Prostate Cancer